Details of the Drug Combination

General Information of Drug Combination (ID: DCUW1HF)

Drug Combination Name

Amonafide Aminolevulinic Acid Hydrochloride

Indication

Disease Entry	Status	REF
Adult acute myeloid leukemia	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Aminolevulinic Acid Hydrochloride DMWNHPC

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: HL-60(TB)

Zero Interaction Potency (ZIP) Score: 5.96

Bliss Independence Score: 6.43

Loewe Additivity Score: 3.08

LHighest Single Agent (HSA) Score: 7.93

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Amonafide

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]

Indication(s) of Aminolevulinic Acid Hydrochloride

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Approved	[3]

Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Protoporphyrinogen oxidase (PPOX)	TTNFMS9	PPOX_HUMAN	Modulator	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCY4Q3B	HCT116	Investigative	[1]
Adenocarcinoma	DCT354A	HT29	Investigative	[1]
Adult T acute lymphoblastic leukemia	DCOXEXE	MOLT-4	Investigative	[1]
Anaplastic large cell lymphoma	DCWNOS3	SR	Investigative	[1]
Clear cell renal cell carcinoma	DCI9PV3	A498	Investigative	[1]
Large cell lung carcinoma	DC1G1MF	NCI-H460	Investigative	[1]
Renal cell carcinoma	DCN50QR	SN12C	Investigative	[1]
Colon adenocarcinoma	DC3MMRI	COLO 205	Investigative	[5]
Invasive ductal carcinoma	DCKTNFA	HS 578T	Investigative	[5]
Invasive ductal carcinoma	DC9QZGS	T-47D	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.